Kantonsspital St.Gallen

Stereotactic radiosurgery and radiotherapy for resected brain metastases: current pattern of care in the Radiosurgery and Stereotactic Radiotherapy Working Group of the German Association for Radiation Oncology (DEGRO) (2022) Rogers S, Baumert BG, Blanck O, Boehmer D, Bostroem J, Engenhart-Cabillic R, Ermis E, et al. Journal article AGO Recommendations for the Surgical Therapy of Breast Cancer: Update 2022 (2022) Banys-Paluchowski M, Thill M, Kuhn T, Ditsch N, Heil J, Woeckel A, Fallenberg E, et al. Journal article Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study) (2022) Rech J, Kleyer A, Ostergaard M, Hagen M, Mendez LV, Tascilar K, Krönke G, et al. Conference contribution Herniation World Federation of Neurosurgical Societies Scale Improves Prediction of Outcome in Patients with Poor-Grade Aneurysmal Subarachnoid Hemorrhage (2022) Raabe A, Beck J, Goldberg J, Źgraggen WJ, Branca M, Marbacher S, D'Alonzo D, et al. Journal article ABATACEPT DELAYS THE DEVELOPMENT OF RA-CLINICAL RESULTS AFTER 18 MONTHS FROM THE RANDOMIZED, PLACEBO-CONTROLLED ARIAA STUDY IN RA-AT RISK PATIENTS (2022) Rech J, Kleyer A, Ostergaard M, Hagen M, Valor L, Tascilar K, Krönke G, et al. Conference contribution Anatomical study of all carpal and adjoining bones of the wrist using 3D CT reconstruction –Finding the ultimate biomechanical theory (2022) Gill D, Lyer S, Alexiou C, Fried F, Buder T, Neuhuber W, Jacxsens M, et al. Journal article Etiology, 3-Month Functional Outcome and Recurrent Events in Non-Traumatic Intracerebral Hemorrhage (2022) Goeldlin MB, Mueller A, Siepen BM, Mueller M, Strambo D, Michel P, Schaerer M, et al. Journal article Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment (2022) Marme F, Hanusch C, Furlanetto J, Morris P, Link T, Denkert C, Fasching P, et al. Conference contribution Intermediate biopsies during neoadjuvant chemotherapy for breast cancer to predict patient outcome (2022) Sinn BV, Untch M, Karn T, Van Mackelenbergh M, Huober J, Sychra K, Schmitt WD, et al. Conference contribution Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC) (2022) Reinisch M, Blohmer JU, Link T, Just M, Untch M, Stoetzer O, Fasching P, et al. Conference contribution